Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 12 Best Australian Stocks to Buy Right Now. On August 8, the company announced positive new patient-reported outcomes from participants in its RePOSA Phase 2 trial of IHL-42X to treat obstructive sleep apnoea (OSA).

Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea

A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture.

The new insights were collected through exit interviews, in line with FDA’s guidance on Patient-Focused Drug Development (PFDD). The results build on already compelling data to reinforce the potential of IHL-42X to improve sleep quality, cognitive function, and daily life.

Incannex Healthcare Inc. (NASDAQ:IXHL) said that 57.6% of the respondents reported an improvement in their OSA, of which 89.5% described it as a meaningful change to their lives. Some of the reported benefits include better sleep quality, reduced sleepiness during the daytime, feeling fresh in the morning, and other cognitive and daily-life improvements.

Joel Latham, President and CEO of Incannex Healthcare Inc. (NASDAQ:IXHL) stated the following on the findings:

“Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug’s potential. We believe the findings from the patient exit interviews underscore that these improvements are not just clinical—they are translating into meaningful, positive changes in patients’ daily lives. This reinforces our belief that IHL-42X has the potential to significantly shift the treatment paradigm for OSA.”

Incannex Healthcare Inc. (NASDAQ:IXHL) is a clinical-stage pharmaceutical company developing medicines to treat chronic conditions, including obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.

While we acknowledge the risk and potential of IXHL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IXHL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now.

Disclosure: None.